Table 1.
Tumor volume doubling time of all experimental groups in therapy studies.
| Experimental groups | Tumor volume doubling time (days) |
|---|---|
| Control | 3 |
| Cold peptide(~5 μg @ day 0)* | 3 |
| 177Lu-3PRGD2 (111 MBq @ day 0) | 11 |
| 177Lu-3PRGD2 (111 MBq × 2 @ day 0 and day 6) | 28 |
| Endostar treatment (i.p. 8 mg/kg/day for two weeks)# | 5 |
| 177Lu-3PRGD2 + Endostar (i.p.)# | 15 |
| Endostar treatment (peritumoral s.c.) | 21 |
| 177Lu-3PRGD2 + Endostar (peritumoral s.c.) | >28 |
| 90Y-3PRGD2 (37 MBq @ day 0)* | 7 |
| 90Y-3PRGK2 (37 MBq @ day 0)* | 4 |
| 90Y-RGD4 (37 MBq @ day 0)* | 6 |
| 90Y-RGD4 (18.5 MBq @ day 0)* | 3 |
| 90Y-RGD4 (18.5 MBq × 2 @ day 0 and day 6)* | 5 |
Note:
#: data showed in supplementary material (Fig S1-2).
*: data from previous paper 24. The 3PRGK2 is a nonsense counterpart of 3PRGD2.
Endostar treatment was administrated at 8 mg/kg daily for two weeks via either i.p. or peritumoral s.c. route.
All the single dose of 177Lu-3PRGD2 (111 MBq) in combination therapy was administrated on day 0.